S&P 500   4,288.39 (+0.01%)
DOW   33,433.35 (-0.22%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.97%)
MU   67.96 (-0.10%)
CGC   0.74 (-6.35%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.16 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
S&P 500   4,288.39 (+0.01%)
DOW   33,433.35 (-0.22%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.97%)
MU   67.96 (-0.10%)
CGC   0.74 (-6.35%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.16 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
S&P 500   4,288.39 (+0.01%)
DOW   33,433.35 (-0.22%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.97%)
MU   67.96 (-0.10%)
CGC   0.74 (-6.35%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.16 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
S&P 500   4,288.39 (+0.01%)
DOW   33,433.35 (-0.22%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.97%)
MU   67.96 (-0.10%)
CGC   0.74 (-6.35%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.16 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
NASDAQ:AGLE

Aeglea BioTherapeutics (AGLE) Stock Forecast, Price & News

$11.70
-0.55 (-4.49%)
(As of 10/2/2023 ET)
Compare
Today's Range
$11.28
$12.25
50-Day Range
$10.86
$15.02
52-Week Range
$2.66
$39.00
Volume
22,821 shs
Average Volume
104,988 shs
Market Capitalization
$47.39 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$24.38

Aeglea BioTherapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
108.3% Upside
$24.38 Price Target
Short Interest
Healthy
3.30% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.62mentions of Aeglea BioTherapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.95) to ($1.56) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.89 out of 5 stars

Medical Sector

729th out of 969 stocks

Pharmaceutical Preparations Industry

351st out of 452 stocks


AGLE stock logo

About Aeglea BioTherapeutics (NASDAQ:AGLE) Stock

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of rare metabolic diseases. The company's therapeutic candidates include pegtarviliase, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria; and pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. In addition, its preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.

AGLE Price History

AGLE Stock News Headlines

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Short Interest Update
Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
Aeglea Biotherapeutics (AGLE) Gets a Buy from Stifel Nicolaus
Aeglea BioTherapeutics Announces Reverse Stock Split
Aeglea BioTherapeutics Appoints Scott Burrows As Chief Financial Officer
Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
Aeglea BioTherapeutics (NASDAQ: AGLE)
Funding wrap: Former Dell Med dean raises $30M
See More Headlines
Receive AGLE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aeglea BioTherapeutics and its competitors with MarketBeat's FREE daily newsletter.

AGLE Company Calendar

Last Earnings
8/11/2023
Today
10/02/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AGLE
Employees
14
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$24.38
High Stock Price Forecast
$37.50
Low Stock Price Forecast
$12.50
Forecasted Upside/Downside
+99.0%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
6 Analysts

Profitability

Net Income
$-83,820,000.00
Net Margins
-22,195.36%
Pretax Margin
-22,209.53%

Debt

Sales & Book Value

Annual Sales
$2.33 million
Book Value
$20.45 per share

Miscellaneous

Free Float
3,918,000
Market Cap
$49.61 million
Optionable
Optionable
Beta
2.53
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. Jonathan D. Alspaugh M.B.A. (Age 40)
    Strategic Advisor
    Comp: $568.55k
  • Mr. James Paul Kastenmayer J.D. (Age 51)
    Ph.D., Consultant
    Comp: $611.84k
  • Mr. Scott L. Burrows (Age 46)
    Chief Financial Officer
  • Dr. Cameron Turtle DPHIL (Age 33)
    Ph.D., Chief Operating Officer
  • Joey Perrone
    VP of Fin. & Investor Relations
  • Ms. Heidy Abreu King-Jones J.D. (Age 40)
    L.L.M., Chief Legal Officer & Corp. Sec.
  • Dr. Kelly Boothe Ph.D.
    Sr. Director of Corp. Communications & Investor Relations













AGLE Stock - Frequently Asked Questions

Should I buy or sell Aeglea BioTherapeutics stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aeglea BioTherapeutics in the last twelve months. There are currently 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" AGLE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AGLE, but not buy additional shares or sell existing shares.
View AGLE analyst ratings
or view top-rated stocks.

What is Aeglea BioTherapeutics' stock price forecast for 2023?

6 equities research analysts have issued 12 month target prices for Aeglea BioTherapeutics' shares. Their AGLE share price forecasts range from $12.50 to $37.50. On average, they predict the company's share price to reach $24.38 in the next twelve months. This suggests a possible upside of 99.0% from the stock's current price.
View analysts price targets for AGLE
or view top-rated stocks among Wall Street analysts.

How have AGLE shares performed in 2023?

Aeglea BioTherapeutics' stock was trading at $11.2475 at the beginning of 2023. Since then, AGLE shares have increased by 8.9% and is now trading at $12.25.
View the best growth stocks for 2023 here
.

Are investors shorting Aeglea BioTherapeutics?

Aeglea BioTherapeutics saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 121,200 shares, an increase of 96.8% from the August 31st total of 61,600 shares. Based on an average trading volume of 76,700 shares, the days-to-cover ratio is currently 1.6 days. Approximately 3.3% of the company's shares are sold short.
View Aeglea BioTherapeutics' Short Interest
.

When is Aeglea BioTherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our AGLE earnings forecast
.

How were Aeglea BioTherapeutics' earnings last quarter?

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) released its quarterly earnings results on Friday, August, 11th. The biotechnology company reported ($41.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($4.50) by $37.00. The biotechnology company had revenue of $0.69 million for the quarter. Aeglea BioTherapeutics had a negative net margin of 22,195.36% and a negative trailing twelve-month return on equity of 132.05%.

When did Aeglea BioTherapeutics' stock split?

Shares of Aeglea BioTherapeutics reverse split on the morning of Friday, September 8th 2023. The 1-25 reverse split was announced on Thursday, September 7th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, September 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What is Anthony Quinn's approval rating as Aeglea BioTherapeutics' CEO?

3 employees have rated Aeglea BioTherapeutics Chief Executive Officer Anthony Quinn on Glassdoor.com. Anthony Quinn has an approval rating of 100% among the company's employees. This puts Anthony Quinn in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Aeglea BioTherapeutics own?
When did Aeglea BioTherapeutics IPO?

(AGLE) raised $60 million in an initial public offering (IPO) on Thursday, April 7th 2016. The company issued 3,500,000 shares at a price of $16.00-$18.00 per share. UBS Investment Bank, BMO Capital Markets and Wells Fargo Securities served as the underwriters for the IPO and Needham & Company was co-manager.

What is Aeglea BioTherapeutics' stock symbol?

Aeglea BioTherapeutics trades on the NASDAQ under the ticker symbol "AGLE."

How do I buy shares of Aeglea BioTherapeutics?

Shares of AGLE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aeglea BioTherapeutics' stock price today?

One share of AGLE stock can currently be purchased for approximately $12.25.

How much money does Aeglea BioTherapeutics make?

Aeglea BioTherapeutics (NASDAQ:AGLE) has a market capitalization of $49.61 million and generates $2.33 million in revenue each year. The biotechnology company earns $-83,820,000.00 in net income (profit) each year or ($71.00) on an earnings per share basis.

How can I contact Aeglea BioTherapeutics?

Aeglea BioTherapeutics' mailing address is 805 LAS CIMAS PARKWAY SUITE 100, AUSTIN TX, 78746. The official website for the company is www.aegleabio.com. The biotechnology company can be reached via phone at (512) 942-2935, via email at investors@aegleabio.com, or via fax at 512-872-5121.

This page (NASDAQ:AGLE) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -